4.90
0.20 (4.26%)
| Penutupan Terdahulu | 4.70 |
| Buka | 4.80 |
| Jumlah Dagangan | 3,599 |
| Purata Dagangan (3B) | 18,676 |
| Modal Pasaran | 48,470,704 |
| Harga / Pendapatan (P/E TTM) | 30.63 |
| Harga / Buku (P/B) | 78.09 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Mar 2025 - 24 Mar 2025 |
| Margin Operasi (TTM) | 29,092.86% |
| EPS Cair (TTM) | -1.51 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -51.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -19.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 90.75% |
| Nisbah Semasa (MRQ) | 2.40 |
| Aliran Tunai Operasi (OCF TTM) | -17.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.94 M |
| Pulangan Atas Aset (ROA TTM) | -124.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -485.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Serina Therapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.60 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 61.81% |
| % Dimiliki oleh Institusi | 3.21% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Broadwood Capital Inc | 31 Dec 2024 | 85,219 |
| Waverly Advisors, Llc | 31 Dec 2024 | 67,492 |
| Keel Point, Llc | 31 Dec 2024 | 17,774 |
| Piscataqua Savings Bank | 31 Dec 2024 | 28 |
| Riggs Asset Managment Co. Inc. | 31 Dec 2024 | 24 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LEDGER STEVEN A | 5.29 | - | 95,730 | 506,412 |
| Jumlah Keseluruhan Kuantiti Bersih | 95,730 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 506,412 | |||
| Purata Pembelian Keseluruhan ($) | 5.29 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LEDGER STEVEN A | Pegawai | 28 Mar 2025 | Diperolehi (+) | 95,730 | 5.29 | 506,412 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Apr 2025 | Pengumuman | Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease |
| 07 Apr 2025 | Pengumuman | Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference |
| 24 Mar 2025 | Pengumuman | Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting |
| 24 Mar 2025 | Pengumuman | Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights |
| 12 Feb 2025 | Pengumuman | Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors |
| 03 Feb 2025 | Pengumuman | Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients |
| 15 Jan 2025 | Pengumuman | Serina Therapeutics Announces Sale of UniverXome Subsidiary |
| 14 Jan 2025 | Pengumuman | Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |